Healthy Males Clinical Trial
Official title:
Relative Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations In Healthy Volunteers Under Fasting Conditions.
NCT number | NCT00902512 |
Other study ID # | A1481267 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | April 2009 |
Est. completion date | April 2009 |
Verified date | January 2021 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
the pharmacokinetics of sildenafil following single doses of sildenafil CT administered with and without water is similar relative to the conventional oral tablet of sildenafil administered with water.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 2009 |
Est. primary completion date | April 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Only healthy male volunteers in the 18-40 age range will be included. - At the selection visit allowed normal range for vital signs will be: Blood pressure (with the subject sitting down) 90-130mm Hg systolic and 60-90 - The volunteers' health condition will be determined from their complete clinical history by doctors at the clinical research site and lab test results by certified clinical laboratories mm Hg diastolic, heart rate 55-100 bpm , respiratory rate 14-20 respirations per minute. Exclusion Criteria: - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening. - Treatment with a PDE-5 inhibitor within the 4 days preceding the first dose of study medication - History of hypersensitivity to sildenafil citrate or any components of its formulations |
Country | Name | City | State |
---|---|---|---|
Mexico | Pfizer Investigational Site | Col. Arenal Tepepan | Mexico D.F. |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC0-T and Cmax of sildenafil | 28 days | ||
Secondary | AUC0-inf of sildenafil | 28 days | ||
Secondary | Tmax and half-life of sildenafil | 28 days | ||
Secondary | Adverse events and vital signs | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04234594 -
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
|
Phase 1 | |
Completed |
NCT01367561 -
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
|
Phase 1 | |
Completed |
NCT00777543 -
Increasing Ferulic Acid Bioavailability in Bran
|
N/A | |
Recruiting |
NCT04756635 -
Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity
|
N/A | |
Completed |
NCT02156661 -
Oxytocin and Emotion Processing
|
Phase 1 | |
Completed |
NCT01848665 -
The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress
|
Phase 4 | |
Completed |
NCT05294198 -
Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males
|
N/A | |
Completed |
NCT00839319 -
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
|
Phase 1/Phase 2 | |
Completed |
NCT00842751 -
Oral T7 Oral Testosterone in Man
|
Phase 2 | |
Completed |
NCT01847053 -
Bioavailability Study of Cinnamon in Healthy Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT01215292 -
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
|
Phase 1/Phase 2 | |
Completed |
NCT00782392 -
Bioavailability and Dosing of a Monosaccharide Supplement in Adults
|
N/A | |
Completed |
NCT03714685 -
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
|
Phase 1 | |
Completed |
NCT05277597 -
Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota
|
N/A | |
Completed |
NCT01032616 -
Uptake and Utilization of Amino Acids by Splanchnic Bed
|
Phase 1 | |
Completed |
NCT01830335 -
Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress
|
Phase 4 | |
Completed |
NCT00475371 -
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
|
Phase 1 | |
Completed |
NCT01870102 -
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
|
Phase 1 |